Hostname: page-component-586b7cd67f-2brh9 Total loading time: 0 Render date: 2024-11-25T07:07:52.806Z Has data issue: false hasContentIssue false
  • English
  • Français

The Pharmacological Treatment of Autistic Spectrum Disorders

Published online by Cambridge University Press:  07 November 2014

Thomas Owley
Get access Rights & Permissions [Opens in a new window]

Abstract

What role do medications play in the overall treatment of autistic spectrum disorders? In this review, the decision-making process involving identifying symptoms, initiating a pharmacological intervention, and monitoring that process is discussed. A review of the literature with an emphasis on controlled trials in autistic spectrum disorders is also undertaken.

Type
Feature Article
Information
CNS Spectrums , Volume 7 , Issue 9 , September 2002 , pp. 663 - 669
Copyright
Copyright © Cambridge University Press 2002

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

REFERENCES

1.Cook, EH Jr., Rowlett, R, Jaselskis, C, Leventhal, BL. Fluoxetine treatment of children and adults with autistic disorder and mental retardation. J Am Acad Child Adolesc Psychiatry. 1992;31;739–745.CrossRefGoogle ScholarPubMed
2.Gordon, C, State, R, Nelson, J, Hamburger, S, Rapoport, J. A double-blind comparison of clomipramine, desipramine, and placebo in the treatment of autistic disorder. Arch Gen Psychiatry. 1993;50:441–447.CrossRefGoogle ScholarPubMed
3.Awad, GA. The use of selective serotonin reuptake inhibitors in young children with pervasive developmental disorders: some clinical observations. Can J Psychiatry. 1996;41:361–366.CrossRefGoogle ScholarPubMed
4.Brodkin, ES, McDougle, CJ, Naylor, ST, Cohen, DJ, Price, LH. Clomipramine in adults with pervasive developmental disorders: a prospective openlabel investigation. J Child Adolesc Psychopharmacol. 1997;7:109–121.CrossRefGoogle ScholarPubMed
5.McDougle, CJ, Epperson, CN, Price, LH, Gelernter, J. Evidence for linkage disequilibrium between serotonin transporter protein gene (SLC6A4) and obsessive compulsive disorder. Mol Psychiatry. 1998;3:270–273.CrossRefGoogle ScholarPubMed
6.Posey, DJ, Walsh, KH, Wilson, GA, McDougle, CJ. Risperidone in the treatment of two very young children with autism. J Child Adolesc Psychopharmacol. 1999;9:273–276.CrossRefGoogle ScholarPubMed
7.Chaziuddin, M, Tsai, L, Ghaziuddin, N. Fluoxetine in autism with depression. J Am Acad Child Adolesc Psychiatry. 1991;30:508–509.CrossRefGoogle Scholar
8.Kroenke, K, West, SL, Swindle, R, Gilsenan, A, Eckert, CJ, Dolor, R, et al.Similar effectiveness of paroxetine, fluoxetine, and sertraline in primary care: a randomized trial. JAMA. 2001;286:2947–2955.CrossRefGoogle ScholarPubMed
9.Goodman, WK, McDougle, CJ, Price, LH. Pharmacotherapy of obsessive-compulsive disorder. J Clin Psychiatry. 1992;53(suppl):29–37.Google ScholarPubMed
10.Remington, G, Sloman, L, Konstantareas, M, Parker, K, Gow, R. Clomipramine versus haloperidol in the treatment of autistic disorder: a double-blind, placebo-controlled, crossover study. J Clin Psychopharmacol. 2001;21:440–444.CrossRefGoogle ScholarPubMed
11.Cook, E, Rowlett, R, Jaselskis, C, Leventhal, B. Fluoxetine treatment of patients with autism and mental retardation. J Am Acad Child Adolesc Psychiatry. 1992;31:739–745.CrossRefGoogle ScholarPubMed
12.Ilellings, JA, Kelley, LA, Gabrielli, WF, Kilgore, E, Shah, P. Sertraline response in adults with mental retardation and autistic disorder. J Clin Psychiatry. 1996;57:333–336.Google Scholar
13.Posey, DJ, McDougle, CJ. Pharmacotherapeutic management of autism. Expert Opin Pharmacother. 2001;2:587–600.CrossRefGoogle ScholarPubMed
14.Cook, E, Leventhal, B. The serotonin system in autism. Curr Opin Pediatr. 1996:8:348–354.CrossRefGoogle ScholarPubMed
15.Aman, MG, Van Bourgondien, ME, Wolford, PL, Sarphare, G. Psychotropic and anticonvulsant drugs in subjects with autism: prevalence and patterns of use. J Am Acad Child Adolesc Psychiatry. 1995;34:1672–1681.CrossRefGoogle ScholarPubMed
16.Martin, A, Scahill, L, Klin, A, Volkmar, FR. Higher-functioning pervasive developmental disorders: rates and patterns of psychotropic drug use. J Am Acad Child Adolesc Psychiatry. 1999;38:923–931.CrossRefGoogle ScholarPubMed
17.Klin, A, Volkmar, F, Schultz, R, Pauls, D, Cohen, DJ. Asperger's syndrome: phenomenology, neuropsychology, and neurobiology. Paper presented at: the 44th Annual Meeting of the American Academy of Child and Adolescent Psychiatry. Toronto, Canada: October 16, 1997.Google Scholar
18.Aman, M, Langworthy, K. Pharmacotherapy for hyperactivity in children with autism and other pervasive developmental disorders. J Autism Dev Disord. 2000;30:451–459.CrossRefGoogle ScholarPubMed
19.Campbell, M, Fish, B, David, R, Shapiro, T, Collins, P, Koh, C. Response to triiodothyronine and dextroamphetamine: a study of preschool schizophrenic children. J Autism Child Schizophr. 1972;2:343–358.CrossRefGoogle ScholarPubMed
20.Campbell, M, Small, AM, Collins, PJ, Friedman, E, David, R, Genieser, N. Levodopa and levoamphetamine: a crossover study in young schizophrenicchildren. Curr Ther Res Clin Exp. 1976;19:70–86.21.Google Scholar
21.Birmaher, B, Quintana, H, Greenhill, LL. Methylphenidate treatment of hyperactive autistic children. J Am Acad Child Adolesc Psychiatry. 1988;27:248–251.CrossRefGoogle ScholarPubMed
22.Yuwiler, A, Brammer, GL, Morley, JE, Raleigh, MJ, Flannery, JW, Geller, E. Short-term and repetitive administration of oral tryptophan in normal men –effects on blood tryptophan, serotonin, and kynurenine concentrations. Arch Gen Psychiatry. 1981;38:619–626.CrossRefGoogle ScholarPubMed
23.Realmuto, GM, August, GJ, Garfinkel, B. Clinical effect of buspirone in autistic children. J Clin Psychopharmacol. 1989;9:122–125.CrossRefGoogle ScholarPubMed
24.Schmidt, K. The effect of stimulant medication in childhood-onset pervasive developmental disorder–a case report. J Dev Behav Pediatr. 1982;3:244–246.CrossRefGoogle ScholarPubMed
25.Sporn, A, Pinsker, H. Use of stimulant medication in treating pervasive developmental disorder. Am J Psychiatry. 1981;138:997.Google ScholarPubMed
26.Strayhorn, JM Jr. Rapp, N, Donina, W, Strain, PS. Randomized trial of methylphenidate for an autistic child. J Am Acad Child Adolesc Psychiatry. 1988;27:244–247.CrossRefGoogle ScholarPubMed
27.Vitriol, C, Farber, B. Stimulant medication in certain childhood disorders. Am J Psychiatry. 1981;138:1517–1518.Google ScholarPubMed
28.Volkmar, FR, Stier, DM, Cohen, DJ. Age of recognition of pervasive developmental disorder. Am J Psychiatry. 1985;142:1450–1452.Google ScholarPubMed
29.Quintana, H, Birmaher, B, Stedge, D, et al.Use of methylphenidate in the treatment of children with autistic disorder. J Autism Dev Disord. 1995;25:283–294.CrossRefGoogle ScholarPubMed
30.Handen, BL, Johnson, CR, Lubetsky, M. Efficacy of methylphenidate among children with autism and symptoms of attention-deficit hyperactivity disorder. J Autism Dev Disord. 2000;30:245–255.CrossRefGoogle ScholarPubMed
31.Jaselskis, CA, Cook, EH, Fletcher, KE, Leventhal, BL. Clonidine treatment of hyperactive and impulsive children with autistic disorder. J Clin Psychopharmacol. 1992;12:322–327.CrossRefGoogle ScholarPubMed
32.Fankhauser, MP, Karumanchi, VC, German, ML, Yates, A, Karumanchi, SD. A double-blind, placebo-controlled study of the efficacy of transdermal clonidine in autism. J Clin Psychiatry. 1992;53:77–82.Google ScholarPubMed
33.Williams, DT, Mehl, R, Yudofsky, S, Adams, D, Roseman, B. The effect of propranolol on uncontrolled rage outbursts in children and adolescents with organic brain dysfunction. J Am Acad Child Adolesc Psychiatry. 1982;21:129–135.CrossRefGoogle ScholarPubMed
34.Ratey, J, Bemporad, J, Sorgi, P, et al.Brief report: open trial effects of betablockers on speech and social behaviors in 8 autistic adults. J Autism Dev Disord. 1987;17:439–446.CrossRefGoogle Scholar
35.Fish, B, Shapiro, T, Campbell, M. Long-term prognosis and the response of schizophrenic children to drug therapy: A controlled study of trifluoperazine. Am J Psychiatry. 1966;123:32–39.CrossRefGoogle ScholarPubMed
36.Campbell, M, Anderson, LT, Meier, M, et al.A comparison of haloperidol and behavior therapy and their interaction in autistic children. J Am Acad Child Psychiatry. 1976;17:640–655.CrossRefGoogle Scholar
37.Cohen, IL, Campbell, M, Posner, D, Small, AM, Triebel, D, Anderson, LT. Behavioral effects of haloperidol in young autistic children. An objective analysis using a within subject reversal design. J Am Acad Child Psychiatry. 1980;19:665–677.CrossRefGoogle ScholarPubMed
38.Naruse, H, Nagahata, M, Nakane, Y, Shirahashi, K, Takesada, M, Yamazaki, K. A multi-center double-blind trial of pimozide (Orap), haloperidol and placebo in children with behavioral disorders, using crossover design. Acta Paedopsychiat. 1982;48:173–184.Google ScholarPubMed
39.Anderson, LT, Campbell, M, Grega, DM, Perry, R, Small, AM, Green, WH. Haloperidol in the treatment of infantile autism: Effects on learning and behavioral symptoms. Am J Psychiatry. 1984;141:1195–1202.Google ScholarPubMed
40.Anderson, LT, Campbell, M, Adams, P, Small, AM, Perry, R, Shell, J. The effects of haloperidol on discrimination learning and behavioral symptoms in autistic children. J Autism Dev Disord. 1989;9:227–239.CrossRefGoogle Scholar
41.Perry, R, Campbell, M, Adams, P, Lynch, N, Spencer, EK. Long-term efficacy of haloperidol in autistic children: Continuous versus discontinuous drug administration. J Am Acad Child Adolesc Psychiatry. 1989;28:87–92.CrossRefGoogle ScholarPubMed
42.Ernst, M, Magee, HJ, Gonzalez, NM, Locascio, JJ, Rosenberg, CR, Campbell, M. Pimozide in autistic children. Psychopharmacol Bull. 1992;28:187–191.Google ScholarPubMed
43.Campbell, M, Adams, P, Perry, R, Spencer, EK, Overall, JE. Tardive and withdrawal dyskinesia in autistic children: a prospective study. Psychopharmacol Bull. 1988;24:251–255.Google ScholarPubMed
44.Wilmut, I, Schnieke, AE, McWhir, J, Kind, AJ, Campbell, KHS. Viable offspring derived from fetal and adult mammalian cells. Nature. 1997;385:810–813.CrossRefGoogle ScholarPubMed
45.McDougle, CJ, Holmes, JP, Bronson, MR, et al.Risperidone treatment of children and adolescents with pervasive developmental disorders: a prospective open-label study. J Am Acad Child Adolesc Psychiatry. 1997;36:685–693.CrossRefGoogle ScholarPubMed
46.Unis, A, Cook, E, Vincent, J, Gjerde, D, Perry, B, Mason, C, et al.Platelet serotonin measures in adolescents with conduct disorder. Biol Psychiatry. 1997;42:553–559.CrossRefGoogle ScholarPubMed
47.Barber, J, Cross, I, Douglas, F, Nicholson, J, Moore, K, Browne, C. Neurofibromatosis pseudogene amplification underlies euchromatic cytogenetic duplications and triplications of proximal 15q. Hum Genet. 1998;103:600–607.CrossRefGoogle ScholarPubMed
48.Potenza, MN, Holmes, JP, Kanes, SJ, McDougle, CJ. Olanzapine treatment of children, adolescents, and adults with pervasive developmental disorders: an open-label pilot study. J Clin Psychopharmacol. 1999;19:37–44.CrossRefGoogle ScholarPubMed
49.Masi, G, Cosenza, A, Mucci, M, Brovedani, P. Open trial of risperidone in 24 young children with pervasive developmental disorders. J Am Acad Child Adolesc Psychiatry. 2001;40:1206–1214.CrossRefGoogle ScholarPubMed
50.McDougle, CJ, Holmes, JP, Carlson, DC, Pelton, GH, Cohen, DJ, Price, LH. A double-blind, placebo-controlled study of risperidone in adults with autistic disorder and other pervasive developmental disorders. Arch Gen Psychiatry. 1998;55:633–641.CrossRefGoogle ScholarPubMed
51.Hellings, JA, Zarcone, JR, Crandall, K, Wallace, D, Schroeder, SR. Weight gain in a controlled study of risperidone in children, adolescents and adults with mental retardation and autism. J Child Adolesc Psychopharmacol. 2001;11:229–238.CrossRefGoogle Scholar
52.Volkmar, FR, Nelson, DS. Seizure disorders in autism. J Am Acad Child Adolesc Psychiatry. 1990;29:127–129.CrossRefGoogle ScholarPubMed
53.Di Martino, A, Tuchman, RF. Antiepileptic drugs: affective use in autism spectrum disorders. Pediatr Neurol. 2001;25:199–207.CrossRefGoogle ScholarPubMed
54.Plioplys, A. Autism: Electroencephalographic abnormalities and clinical improvement with valproic acid. Arch Pediatr Adolesc Med. 1994;148:220–222.CrossRefGoogle Scholar
55.Childs, JA, Blair, JL. Valproic acid treatment of epilepsy in autistic twins. J Neurosci Nurs. 1997;29:244–248.CrossRefGoogle ScholarPubMed
56.Damore, J, Stine, J, Brody, L. Medication-induced hypomania in Asperger's disorder. J Am Acad Child Adolesc Psychiatry. 1998;37:248–249.CrossRefGoogle ScholarPubMed
57.Hollander, E, Dolgoff-Kaspar, R, Cartwright, C, Rawitt, R, Novotny, S. An open trial of divalproex sodium in autism spectrum disorders. J Clin Psychiatry. 2001;62:530–534.CrossRefGoogle ScholarPubMed
58.Deonna, T, Ziegler, AL, Moura-Serra, J, Innocenti, G. Autistic regression in relation to limbic pathology and epilepsy: report of two cases. Dev Med Child Neurol. 1993;35:166–176.CrossRefGoogle ScholarPubMed
59.Komoto, J, Usui, S, Hirata, J. Infantile autism and affective disorder. J Autism Dev Disord. 1984;14:81–84.CrossRefGoogle ScholarPubMed
60.Belsito, K, Law, P, Kirk, K, Landa, R, Zimmerman, A. Lamotrigine therapy for autistic disorder: A randomized, double-blind, placebo-controlled trial. J Autism Dev Disord. 2001;31:175–181.CrossRefGoogle ScholarPubMed
61.King, B. Wright, D, Handen, B, et al.A double-blind, placebo-controlled study of amantidine hydrochloride in the treatment of children with autistic disorder. J Am Acad Child Adolesc Psychiatry. 2001;40:658–665.CrossRefGoogle ScholarPubMed
62.Brent, DA, Crumrine, PK, Varma, RR, Allan, M, Allman, C. Phenobarbital treatment and major depressive disorder in children with epilepsy. Pediatrics. 1987;80:909–917.Google ScholarPubMed
63.Vining, EPG, Mellits, D, et al.Psychologic and behavioral effects of antiepileptic drugs in children: a double-blind comparison between phenobarbital and valproic acid. Pediatrics. 1987;80:165–174.CrossRefGoogle ScholarPubMed
64.Campbell, M, Anderson, L, Small, A, Adams, P, Gonzalez, N, Ernst, M. Naltrexone in autistic children: behavioral symptoms and attentional learning. J Am Acad Child Adolesc Psychiatry. 1993;32:1283–1291.CrossRefGoogle ScholarPubMed
65.Zingarelli, G, Ellman, G, Hom, A, Wymore, M, Heidorn, S, Chicz-DeMet, A. Clinical effects of naltrexone on autistic behavior. Am J Ment Retard. 1992;97:57–63.Google ScholarPubMed
66.Willemsen-Swinkels, SHN, Buitelaar, JK, Weijnen, FG, Van Engeland, H. Placebo-controlled acute dosage naltrexone study in young autistic children. Psychiatry. Research 1995;58:203–215.CrossRefGoogle ScholarPubMed
67.Herman, B, Asleson, G, Papero, P. Acute and chronic naltrexone decreases the hyperactivity of autism. Abstr Soc Neurosci. 1993:Abstract 732.3.Google Scholar
68.Willemsen-Swinkels, SHN, Buitelaar, JK, Van Engeland, H. The effects of chronic naltrexone treatment in young autistic children: a double-blind placebo-controlled crossover study. Biol Psychiatry. 1996;39:1023–1031.CrossRefGoogle ScholarPubMed
69.Willemsen-Swinkels, SH, Buitelaar, JK, van Berckelaer-Onnes, IA, van Engeland, H. Brief report: six months continuation treatment in naltrex-one- responsive children with autism: an open-label case-control design. J Autism Dev Disord. 1999;29:167–169.CrossRefGoogle Scholar
70.Percy, AK, Glaze, DG, Schultz, RJ, Zoghbi, HY, Williamson, D, Frost, J Jr.et al.Rett syndrome: controlled study of an oral opiate antagonist, naltrexone. Ann Neurol. 1994;35:464–470.CrossRefGoogle ScholarPubMed
71.Campbell, M, Fish, B, Korein, J, Shapiro, T, Collins, P, Koh, C. Lithium and chlorpromazine: A controlled crossover study of hyperactive severely disturbed young children. J Autism Child Schizophr. 1972:2:234–263.CrossRefGoogle ScholarPubMed
72.Buitelaar, JK, van der Gaag, RJ, van der Hoeven, J. Buspirone in the management of anxiety and irritability in children with pervasive developmental disorders: results of an open-label study. J Clin Psychiatry. 1998;59:56–59.CrossRefGoogle ScholarPubMed
73.Carlsson, ML. Hypothesis: is infantile autism a hypoglutamatergic disorder? Relevance of glutamate - serotonin interactions for pharmacotherapy. J Neural Transm. 1998;105(4–5):525–535.CrossRefGoogle ScholarPubMed
74.Martineau, J, Barthelemy, C, Cheliakine, C, Lelord, G. Brief report: an open middle-term study of combined vitamin B6- magnesium in a subgroup of autistic children selected on their sensitivity to this treatment. J Autism Dev Disord. 1988;18:435–447.CrossRefGoogle Scholar
75.Kleijnen, J, Knipschild, P. Niacin and vitamin B6 in mental functioning: a review of controlled trials in humans. Biol Psychiatry. 1991;29:931–41.CrossRefGoogle ScholarPubMed
76.Geller, E, Ritvo, ER, Freeman, BJ, Yuwiler, A. Preliminary observations on the effect of fenfluramine on blood serotonin and symptoms in three autistic boys. N Eng J Med. 1982;307:165–169.CrossRefGoogle ScholarPubMed
77.Aman, MG, Kern, RA. Review of fenfluramine in the treatment of the developmental disabilities. J Amer Acad Child Adolesc Psychiatry. 1989;28:549–565.CrossRefGoogle ScholarPubMed
78.Leventhal, BL, Cook, EH Jr, Morford, M, Ravitz, AJ, Heller, W, Freedman, DX. Clinical and neurochemical effects of fenfluramine in children with autism. J Neuropsychiatry Clin Neurosci. 1993:5:307–315.Google ScholarPubMed
79.Aman, MG, Kern, RA, Arnold, LE, McGhee, DE. Fenfluramine and mental retardation. J Am Acad Child Adolesc Psychiatry. 1991;30:507–508.CrossRefGoogle ScholarPubMed
80.Schuster, CR, Lewis, M, Seiden, LS. Fenfluramine: neurotoxicity. Psychopharm Bull. 1986;22:148–151.Google ScholarPubMed
81.Horvath, K, Stefanatos, G, Sokolski, KN, Wachtel, R, Nabors, L, Tildon, JT. Improved social and language skills after secretin administration in patients with autistic spectrum disorders. J Assoc Acad Minor Phys. 1998;9:9–15.Google ScholarPubMed
82.Sandler, AD, Sutton, KA, DeWeese, J, Girardi, MA, Sheppard, V, Bodfish, JW. Lack of benefit of a single dose of synthetic human secretin in the treatment of autism and pervasive developmental disorder. N Engl J Med. 1999;341:1801–1806.CrossRefGoogle ScholarPubMed
83.Chez, MG, Buchanan, CP, Bagan, BT, et al.Secretin and autism: a two-part clinical investigation. J Autism Dev Disord 2000;30:87–94.CrossRefGoogle ScholarPubMed
84.Dunn-Geier, J, Ho, HH, Auersperg, E, et al.Effect of secretin on children with autism: a randomized controlled trial. DevMed Child Neurol. 2000:42:796–802.CrossRefGoogle ScholarPubMed
85.Roberts, W, Weaver, L, Brian, J, et al.Repeated doses of porcine secretin in the treatment of autism: a randomized, placebo-controlled trial. Pediatrics. 2001;107:E71.CrossRefGoogle ScholarPubMed
86.Coniglio, SJ, Lewis, JD, Lang, C, Burns, TG, Subhani-Siddique, R, Weintraub, A, et al.A randomized, double-blind, placebo-controlled trial of single-dose intravenous secretin as treatment for children with autism. J Pediatr. 2001;138:649–655.CrossRefGoogle ScholarPubMed
87.Owley, T, McMahon, W, Cook, EH, et al.Multi-site, double-blind, placebo-controlled trial of porcine secretin in autism. J Am Acad Child Adolesc Psychiatry. 2001;40:1293–1299.CrossRefGoogle Scholar
88.Aman, M. Aberrant Behavior Checklis-Community. East Aurora, NY: Slosson Educational Publications; 1994.Google Scholar